The goals of this study are to identify ASXL2 binding sites in SKNO1 cells Examination of chromatin accessbility in AML1ETO9a leukemia with or without ASXL2
Human iPS cells (WT ASE9203 cells) were obtained from Applied Stem Cell (ASC), and CRISPR-Cas9-mediated gene editing was completed by ASC using their proprietary CRISPR-Cas9 protocol to introduce the
BackgroundCholangiocarcinoma (CCA) is a highly aggressive malignant tumor for which limited treatment methods and prognostic signatures are available. This study aims to identify potential therapeutic
